COVID-19: benefits and risks of passive immunotherapeutics

• Asıl Yazarlar: Ankur Gupta (Yazar), Rashmi Karki (Yazar), Himanshu R Dandu (Yazar), Kuldeep Dhama (Yazar), Madan LB Bhatt (Yazar), Shailendra K Saxena (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Taylor & Francis Group, 2020-12-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since the early twentieth century for the treatment of viral diseases such as severe acute respiratory syndrome (SARS), middle east respira...